Choroidal Imaging Biomarkers in Systemic Disease Detection

Abstract

Choroidal imaging biomarkers have emerged as valuable tools for the detection and monitoring of systemic diseases. The choroid, as a highly vascular structure, reflects systemic vascular and inflammatory changes, enabling non-invasive assessment of systemic disease burden through advanced ophthalmic imaging modalities. Recent evidence demonstrates that choroidal thickness, vascularity, and morphologic alterations are associated with conditions such as diabetes, hypertension, cardiovascular disease, and autoimmune disorders. This review provides a comprehensive overview of the clinical applications, pathophysiological mechanisms, and practical implications of choroidal imaging biomarkers in systemic disease detection, highlighting current guidelines and recent advances relevant to daily clinical practice.

Introduction

The choroid forms a critical component of the ocular vasculature, providing oxygen and nutrients to the outer retina. Advances in ocular imaging, particularly enhanced depth imaging optical coherence tomography (EDI-OCT) and swept-source OCT (SS-OCT), have enabled high-resolution visualization of choroidal structure and vasculature in vivo. Mounting evidence indicates that changes in choroidal metrics can serve as early indicators of systemic disease, offering opportunities for early diagnosis, risk stratification, and monitoring therapeutic response. This article aims to synthesize recent research on choroidal imaging biomarkers and their clinical significance in systemic disease detection.

Epidemiology / Disease Burden

The global prevalence of systemic diseases such as diabetes mellitus, hypertension, and cardiovascular disorders continues to rise, necessitating novel approaches for early detection and monitoring. Epidemiological studies reveal that ocular manifestations often precede systemic symptoms, positioning the eye as a \"window\" into systemic health. Choroidal abnormalities, observable through non-invasive imaging, are commonly detected in patients with chronic systemic illnesses, with prevalence rates varying by disease type and severity. For instance, diabetic choroidopathy has been reported in up to 60% of patients with diabetic retinopathy, while choroidal thinning is frequently observed in hypertensive and cardiovascular cohorts.

Pathophysiology

The choroid is uniquely sensitive to systemic vascular and inflammatory changes due to its dense vascular network and high metabolic demand. Systemic diseases can disrupt choroidal homeostasis via diverse mechanisms, including microvascular compromise, immune-mediated injury, and neurohormonal dysregulation. In diabetes, hyperglycemia leads to choroidal vascular remodeling, increased permeability, and eventual thinning or thickening depending on disease stage. Hypertension induces choroidal arteriolosclerosis and ischemia, manifesting as reduced choroidal thickness and vascular density. Autoimmune diseases such as systemic lupus erythematosus and sarcoidosis can provoke choroidal granulomas or vasculitis, resulting in focal or diffuse choroidal alterations detectable by imaging.

Risk Factors

Risk factors for choroidal involvement in systemic disease mirror those for the underlying systemic condition but may also include ocular-specific determinants. Duration and control of systemic disease, age, genetic predisposition, and concomitant ocular pathology can modulate choroidal changes. For example, poorly controlled diabetes and hypertension are associated with more pronounced choroidal abnormalities, while chronic kidney disease and dyslipidemia may synergistically exacerbate choroidal vascular compromise. Certain medications, such as corticosteroids and immunosuppressants, also impact choroidal structure and function.

Clinical Features

Choroidal changes in systemic disease may be asymptomatic or present with nonspecific visual complaints such as blurred vision, metamorphopsia, or scotomas, often preceding overt retinopathy or vasculopathy. On imaging, features include altered subfoveal choroidal thickness, increased or decreased choroidal vascularity index (CVI), presence of focal choroidal lesions, and disruption of choriocapillaris flow. In diabetes, early choroidal thickening may progress to thinning with advanced disease, while hypertensive choroidopathy can manifest as Elschnig spots or serous retinal detachments. Autoimmune choroidopathies may present with multifocal choroidal infiltrates detectable on OCT and indocyanine green angiography (ICGA).

Diagnosis

Diagnosis of choroidal involvement relies on multimodal imaging, with EDI-OCT and SS-OCT as primary modalities for quantitative assessment of choroidal thickness and structure. OCT angiography (OCTA) offers non-invasive visualization of choriocapillaris flow deficits and vascular remodeling. ICGA remains the gold standard for detecting choroidal vasculitis, granulomas, and hypoperfusion. Choroidal imaging findings should be interpreted in the context of systemic disease history, laboratory results, and other ocular findings to achieve an accurate diagnosis and guide management.

Treatment & Management

Management of choroidal changes in systemic disease is primarily directed at optimizing control of the underlying systemic condition. Tight glycemic and blood pressure control can stabilize or reverse choroidal abnormalities in diabetes and hypertension, respectively. Immunosuppressive therapy is indicated for autoimmune choroidopathies with significant choroidal involvement. Adjunctive ocular therapies, such as intravitreal corticosteroids or anti-vascular endothelial growth factor (VEGF) agents, may be considered in selected cases with sight-threatening complications. Regular choroidal imaging enables monitoring of disease progression and response to therapy.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advances in choroidal imaging technology, with higher-resolution and widefield imaging facilitating detection of subtle or peripheral choroidal changes. Quantitative metrics such as CVI and choroidal vascular flow analysis are being integrated into clinical and research protocols, offering objective biomarkers for systemic disease monitoring. Artificial intelligence and machine learning algorithms are under development to automate choroidal image analysis and risk stratification. Novel systemic therapies targeting vascular inflammation and endothelial function may further impact choroidal health, warranting ongoing research and clinical trials.

Guideline Recommendations

International guidelines increasingly recognize the value of ocular imaging, including choroidal assessment, in the multidisciplinary management of systemic diseases. The American Diabetes Association recommends annual comprehensive eye exams with multimodal imaging for all patients with diabetes. The European Society of Cardiology highlights the role of retinal and choroidal imaging in cardiovascular risk assessment. Rheumatology guidelines endorse ocular imaging for baseline evaluation and monitoring of patients with systemic autoimmune diseases, particularly those with ocular symptoms or at high risk of choroidal involvement.

Conclusion

Choroidal imaging biomarkers represent a promising frontier in the early detection and monitoring of systemic diseases. By reflecting underlying vascular, metabolic, and inflammatory changes, choroidal metrics provide clinicians with valuable insights into systemic disease burden and therapeutic response. Integration of choroidal imaging into routine clinical practice, guided by evidence-based protocols and emerging technologies, holds significant potential to improve patient outcomes in a wide range of systemic disorders.